Navigation Links
Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Date:2/3/2009

Therapeutic Approach Provides HIV-Resistant Immune Cells

RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS.

Based on Sangamo's zinc finger DNA-binding protein nuclease (ZFN) technology, SB-728-T has been shown in an animal model of HIV infection to lead to an increase in CD4+ T-cell counts, a reduction in viral load and expansion of CCR5-modified T-cells, suggesting resistance to HIV.

"This is the first time that we have had the ability to make a patient's T-cells permanently resistant to infection by CCR5-specific strains of HIV and we are very excited to begin a clinical trial of this novel ZFN-based therapy," said Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine. "The ability to protect immune cells from infection with HIV and the expansion of CCR5-modified T-cells has the potential to provide long-term control of both the virus itself and eventually the opportunistic infections characteristic of AIDS."

CCR5 is a co-receptor that enables HIV to enter and infect cells of the immune system. About ten years ago, it was observed that individuals carrying a natural mutation of their CCR5 gene, CCR5-delta32, were highly resistant to infection by HIV. These individuals, lacking a functional CCR5 (approximately 1-2% of the general population), are immunologically "normal". A variety of small molecule and antibody antagonists of CCR5 binding have been tested and developed as potential therapeutic agents for the treatment of HIV infection. In addition, there is a recent report
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
2. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
3. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
5. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
8. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
10. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
11. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., Gabon, December 2 , - "...lem and Heritage" , Coinciding with the I...he,Gabonese Republic is hosting an international c...feguarding biological resources in Africa. The,con...eaders, ministers,scientific experts, private com...
(Date:12/2/2009)...Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald...TC Bulletin Board: EMDY), a leading,producer and d...powder and,soybean products in China, today announ...g issue of US Food & Drink Executive, a quarte...cutives in the food and beverage industry. , ...
(Date:12/2/2009)... Dec. 2 According to the National ...mericans diagnosed with diabetes already have some...thy, damage to the retina caused by leaky blood ve...h diabetes and is one of the most feared diabetic ...atients who,ve had diabetes for 10 years or more w...
(Date:12/1/2009)... Dec. 1 Reportlinker.com announces... its catalogue: ,, Emerging Clinical Trial Loc...hanging healthcare and regulatory environment ,...Clinical-Trial-Locations---Eastern-Europe-Market-d...-environment.html ,, Over the last decade phar...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...s,Inc. (Nasdaq: RNVS ) announced today that its s...reement with Evotec AG (Frankfurt Stock Exchange:,...ay. The merger is,expected to close by May 5, 2008...g share of Renovis common,stock will be automatica...an American Depositary Share (ADSs) of Evotec, wit...
...roMetic Life Sciences Inc.,("ProMetic") (TSX:PLI) ...olders on Wednesday, May 7, 2008 at 10:30 a.m. (ED... ("Meeting") will be held at the Montreal,Museum o... in Montreal.,Points to be covered are:, - Items...ormation Circular - Corporate Presentations, ...
...unced Thursday,that a majority of the company,s sh...e joining the healthcare workflow technology compa...hirty years of executive experience to,Bio-Optroni... headquarters,in Rochester, NY. The company,s prod...ent and optimization solutions for hospitals, spec...
Other Biology Technology:Renovis Stockholders Approve Acquisition by Evotec 2Prometic provides information for its Annual and Special Meeting of Shareholders 2Former GE, Kodak and SGS Executive Dan Kerpelman to Join Bio-Optronics as President and CEO 2
(Date:12/2/2009)... Duke University Medical Center researchers have ...cancer glioma may be better able to resist radiati... signaling pathway in these cancer stem cells, the...diation in a laboratory experiment. , The work ...er stem cells resist the effects of radiation much...
(Date:12/2/2009)... are reporting the first identification of substan... that changes harmless marine bacteria into killer...s in ACS, Environmental Science & Technology , a ...es note that bleaching already has destroyed up to...ists are searching for ways to slow or stop the da...
(Date:12/2/2009)..., December 2, 2009 Commonly prescribed beta 2 adr...in pregnant women as well as pre-term labor may in... psychiatric pathology, cognitive problems and poo...to a new study published in the December 2009 issu...ogy . , Beta 2 adrenergic agonist drugs as a cla...
Breaking Biology News(10 mins):Discovery makes brain tumor cells more responsive to radiation 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma 12872 1New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma 12872 2The Other Cruciate Ligament 3A Newer Treatments for PCL Tears 50542 1The Other Cruciate Ligament 3A Newer Treatments for PCL Tears 50542 2The Other Cruciate Ligament 3A Newer Treatments for PCL Tears 50542 3New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 1New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 2New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 3New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 4New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 5New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 6New Report Finds Obesity Epidemic Increases Mississippi Weighs in as Heaviest State 50539 7
...d tool to combat the worsening malaria epidemic in...leagues (from the Institut Pasteur in Paris) have ... on MSP3, a protein present on the surface of the ..., As the researchers report in the international ... the 30 healthy volunteers who received the vaccin...
...gist and flu expert is calling for mandatory vacci...s of protecting patients and hospital staff from w... by other United States researchers show that volu...at each year, nearly 40,000 Americans die from inf... immune systems that cannot readily fend off the d...
...s week in Nature shows for the first time that a m...ock cells that regulate daily activity of Drosophi...of neurons control morning and evening activity an...plunged into darkness for extended periods of time...rning to the evening cells and maintains a 12-hour...
Other Biology News:Johns Hopkins flu expert calls for mandatory vaccination of health care workers 2Johns Hopkins flu expert calls for mandatory vaccination of health care workers 3A resetting signal keeps circadian rhythm on track in Drosophila fruit flies 2
...c Nebulizers are available in two product models -...hese two models is that the 6000AT+ includes a mem...rier aerosol for improved detection limits and red...ection limits for a range of elements by 10-40 tim...
AMV RT HC 600 U from Invitrogen
T4 DNA Ligase; (1 x 103 U/ml) or (5 x 103 U/ml) supplied with 10x ligation buffer that includes ATP from Roche Applied Science
...lyzes the formation of a phosphodiester bonds betw... nicked duplex DNA molecules or between oligonucle...rand at 45 - 65?. Tfi DNA Ligase is stable and act...DNA ligases, Thus, Tfi DNA Ligase is the ideal enz...
Biology Products: